Foghorn Therapeutics (FHTX) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Foghorn Therapeutics (FHTX) has outperformed Humacyte (HUMA) over the past year, losing 52.7% versus a loss of 71.3%. Over five years, FHTX leads with a -83.1% price change compared with -95.4% for HUMA. Humacyte is the larger company by market cap ($131.2 million vs $124.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | HUMA |
|---|---|---|
| Share price | $2.09 | $0.4723 |
| Market cap | $124.12M | $131.20M |
| 1-day change | +6.09% | -1.19% |
| YTD return | -61.30% | -50.85% |
| 1-year return | -52.71% | -71.29% |
| 5-year return | -83.12% | -95.38% |
| EPS (TTM) | $-0.98 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $1.90 |
| 52-week low | $1.79 | $0.46 |
| Distance from 52-week high | -72.54% | -75.08% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +187.08% | +245.12% |
| Average volume | 616.68K | 6.30M |
| Shares outstanding | 59.39M | 277.80M |
| Employees | 106 | 184 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FHTX has outperformed HUMA by 18.6 percentage points over the past year.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
FHTX vs HUMA FAQ
Which is bigger, Foghorn Therapeutics or Humacyte?
Humacyte (HUMA) is larger, with a market capitalization of $131.20M compared with $124.12M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or HUMA?
FHTX returned -52.71% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Humacyte in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Foghorn Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Humacyte.